Effect of an Integrated, Multidisciplinary Nationwide Approach to Type 1 Diabetes Care on Metabolic Outcomes: An Observational Real-World Study

Objective: Achieving good metabolic control in people with type 1 diabetes (T1D) remains a challenge, despite the evolutions in diabetes technologies over the past decade. Here we investigate the evolution of metabolic control in people with T1D, where care is provided by specialized centers with ac...

Full description

Bibliographic Details
Main Authors: Casteels, K. (Author), Chao, S. (Author), De Block, C. (Author), Doggen, K. (Author), Lavens, A. (Author), Mathieu, C. (Author), Mouraux, T. (Author), Nobels, F. (Author), Oriot, P. (Author), Verhaegen, A. (Author)
Format: Article
Language:English
Published: Mary Ann Liebert Inc. 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 04576nam a2200937Ia 4500
001 10.1089-dia.2021.0003
008 220427s2021 CNT 000 0 und d
020 |a 15209156 (ISSN) 
245 1 0 |a Effect of an Integrated, Multidisciplinary Nationwide Approach to Type 1 Diabetes Care on Metabolic Outcomes: An Observational Real-World Study 
260 0 |b Mary Ann Liebert Inc.  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1089/dia.2021.0003 
520 3 |a Objective: Achieving good metabolic control in people with type 1 diabetes (T1D) remains a challenge, despite the evolutions in diabetes technologies over the past decade. Here we investigate the evolution of metabolic control in people with T1D, where care is provided by specialized centers with access to technology, diabetes education, and regular follow-up. Methods: Data were cross-sectionally collected between 2010 and 2018 from more than 100 centers in Belgium. The evolutions over time of hemoglobin A1C (HbA1c), low-density lipoprotein (LDL) cholesterol, and systolic blood pressure (SBP) were investigated, together with the evolutions of use of insulin pump (continuous subcutaneous insulin infusion [CSII]), continuous glucose monitoring (CGM), and lipid-lowering and antihypertensive drugs. Association of HbA1c with gender, age, diabetes duration, and technology use was analyzed on the most recent cohort. Results: The study population contained data from 89,834 people with T1D (age 1-80 years). Mean HbA1c decreased from 65 mmol/mol (8.1%) in 2010-2011 to 61 mmol/mol (7.7%) in 2017-2018 (P < 0.0001, adjusted for gender, age, diabetes duration, and technology use). Respectively, mean LDL cholesterol decreased from 2.45 mmol/L (94.6 mg/dL) to 2.29 mmol/L (88.5 mg/dL) (P < 0.0001, adjusted for gender, age, and diabetes duration), and mean SBP remained stable. CGM usage increased, whereas the use of CSII and lipid-lowering and antihypertensive drugs remained stable. Gender, age, diabetes duration, and technology use were independently associated with HbA1c. Conclusions: Our real-world data show that metabolic and lipid control improved over time in a system where T1D care is organized through specialized multidisciplinary centers with emphasis on linking education to provision of technology, and its quality is monitored. © 2021, Mary Ann Liebert, Inc., publishers. 
650 0 4 |a adolescent 
650 0 4 |a Adolescent 
650 0 4 |a adult 
650 0 4 |a Adult 
650 0 4 |a aged 
650 0 4 |a Aged 
650 0 4 |a Aged, 80 and over 
650 0 4 |a antihypertensive agent 
650 0 4 |a antilipemic agent 
650 0 4 |a Article 
650 0 4 |a Belgium 
650 0 4 |a Blood Glucose 
650 0 4 |a blood glucose monitoring 
650 0 4 |a Blood Glucose Self-Monitoring 
650 0 4 |a child 
650 0 4 |a Child 
650 0 4 |a Child, Preschool 
650 0 4 |a collaborative care team 
650 0 4 |a continuous infusion 
650 0 4 |a controlled study 
650 0 4 |a cross-sectional study 
650 0 4 |a Diabetes care 
650 0 4 |a diabetes control 
650 0 4 |a diabetes education 
650 0 4 |a Diabetes education 
650 0 4 |a Diabetes Mellitus, Type 1 
650 0 4 |a female 
650 0 4 |a glucose blood level 
650 0 4 |a Glycated Hemoglobin A 
650 0 4 |a glycosylated hemoglobin 
650 0 4 |a HbA1c 
650 0 4 |a hemoglobin A1c 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a infant 
650 0 4 |a Infant 
650 0 4 |a insulin 
650 0 4 |a insulin 
650 0 4 |a Insulin 
650 0 4 |a insulin dependent diabetes mellitus 
650 0 4 |a insulin infusion 
650 0 4 |a Insulin Infusion Systems 
650 0 4 |a low density lipoprotein cholesterol 
650 0 4 |a major clinical study 
650 0 4 |a male 
650 0 4 |a metabolic regulation 
650 0 4 |a middle aged 
650 0 4 |a Middle Aged 
650 0 4 |a multicenter study 
650 0 4 |a patient care 
650 0 4 |a preschool child 
650 0 4 |a Quality assurance program 
650 0 4 |a retrospective study 
650 0 4 |a systolic blood pressure 
650 0 4 |a Type 1 diabetes 
650 0 4 |a very elderly 
650 0 4 |a young adult 
650 0 4 |a Young Adult 
700 1 |a Casteels, K.  |e author 
700 1 |a Chao, S.  |e author 
700 1 |a De Block, C.  |e author 
700 1 |a Doggen, K.  |e author 
700 1 |a Lavens, A.  |e author 
700 1 |a Mathieu, C.  |e author 
700 1 |a Mouraux, T.  |e author 
700 1 |a Nobels, F.  |e author 
700 1 |a Oriot, P.  |e author 
700 1 |a Verhaegen, A.  |e author 
773 |t Diabetes Technology and Therapeutics